AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2025
635
Period ended Dec 31, 2025
Change on a year earlier
+6.7%
595 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 635 | +6.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 595 | -9.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 659 | -12.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 755 | +0.1% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 754 | -3.9% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 785 | -46.7% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 1,473 | -8.7% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 1,614 | +482.7% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 277 | – | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up mavyret (glecaprevir/pibrentasvir — hepatitis c) — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — U.S. net revenues ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/mavyret_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.